
A major milestone for cancer drug development in Taivex! T-1101 OPC initiates Phase I clinical study
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate